What is a preferred angiotensin II receptor blocker-based combination therapy for blood pressure control in hypertensive patients with diabetic and non-diabetic renal impairment?-Reference-Cited by-同舟云学术

What is a preferred angiotensin II receptor blocker-based combination therapy for blood pressure control in hypertensive patients with diabetic and non-diabetic renal impairment?

Published:2012 Issue:1 Volume:11 Page:32
ISSN:1475-2840
Container-title:Cardiovascular Diabetology
language:en
Short-container-title:Cardiovasc Diabetol

Author:

Mallat Samir G

Publisher

Springer Science and Business Media LLC

Subject

Cardiology and Cardiovascular Medicine,Endocrinology, Diabetes and Metabolism

Reference95 articles.

1. US Trends in Prevalence, Awareness, Treatment, and Control of Hypertension, 1988-2008

2. Trends and Cardiovascular Mortality Effects of State-Level Blood Pressure and Uncontrolled Hypertension in the United States

3. Trends in Hypertension Prevalence, Awareness, Treatment, and Control in Older U.S. Adults: Data from the National Health and Nutrition Examination Survey 1988 to 2004

4. Management of hypertension: summary of NICE guidance

5. Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Combination therapy for hypertension management: insights from the Indian experts;International Journal of Scientific Reports;2024-05-23

2. RSSDI Guidelines for the management of hypertension in patients with diabetes mellitus;International Journal of Diabetes in Developing Countries;2022-10

3. Pharmacotherapy to delay the progression of diabetic kidney disease in people with type 2 diabetes: past, present and future;Therapeutic Advances in Endocrinology and Metabolism;2022-01

4. Efficacy of ARB/HCTZ Combination Therapy in Uncontrolled Hypertensive Patients Compared with ARB Monotherapy: A Meta-Analysis;International Journal of Hypertension;2021-04-27

5. Efficacy and safety of Shenyankangfu Tablet, a Chinese patent medicine, for primary glomerulonephritis: A multicenter randomized controlled trial;Journal of Integrative Medicine;2021-03